Pharmacotherapy for Type 2 Diabetes Mellitus: What's Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?

被引：1
|
作者：
Elder, Mary J. [1 ]
Ashjian, Emily J. [2 ]
机构：
[1] Michigan Med, Pharm Innovat & Partnerships, 2500 Green Rd,Suite 100, Ann Arbor, MI 48105 USA
[2] Univ Michigan, Coll Pharm, Dept Clin Pharm, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF PHARMACY PRACTICE | 2023年 / 36卷 / 02期
关键词：
diabetes mellitus; glucagon-like peptide-1 receptor agonist; gastric inhibitory polypeptide; G protein-coupled receptor 119 agonist; glucagon receptor agonist; RECEPTOR AGONIST; CHINESE PATIENTS; DOUBLE-BLIND; PHARMACODYNAMICS; PHARMACOKINETICS; SAFETY; METFORMIN; RG7697; SINGLE;
D O I：
10.1177/08971900211049032
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Glucagon-like peptide-1 (GLP-1), an incretin hormone, is known to lower glucose levels, suppress glucagon secretion, and slow gastric emptying. These properties make GLP-1 an ideal target in treating type 2 diabetes mellitus (T2DM). There are many FDA-approved GLP-1 agonists on the market today, several of which have demonstrated benefit beyond improving glycemic control. Given the beneficial effects of GLP-1 agonists in patients with T2DM, new drugs are in development that combine the mechanism of action of GLP-1 receptor agonism with novel mechanisms and with drugs that promote GLP-1 secretion. These agents are designed to improve glycemic control and target greater body weight reduction. This article discusses new GLP-1 drugs in the pipeline for the treatment of T2DM.
引用
收藏
页码：418 / 428
页数：11
相关论文
共 50 条
  • [21] Facile Synthesis of Glucagon-Like Peptide-1 (GLP-1) Mimetics
    Han, Sun-Young
    Beinborn, Martin
    Ahn, Jung-Mo
    PEPTIDES FOR YOUTH, 2009, 611 : 119 - 120
  • [22] Facile synthesis of glucagon-like peptide-1 (GLP-1) mimetics
    Han, S.-Y.
    Murage, E.
    Beinbom, M.
    Ahn, J.-M.
    BIOPOLYMERS, 2007, 88 (04) : 560 - 560
  • [23] Glucagon-like peptide-1 drugs Are GLP-1 analogues affordable?
    Macaulay, Donald
    BRITISH MEDICAL JOURNAL, 2011, 342
  • [24] GLUCAGON-LIKE PEPTIDE-1 (GLP-1) - A PIECE OF THE INCRETIN PUZZLE
    WEIR, GC
    JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (01): : 1 - 1
  • [25] Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
    Hoelscher, Christian
    CNS DRUGS, 2012, 26 (10) : 871 - 882
  • [26] Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
    Christian Hölscher
    CNS Drugs, 2012, 26 : 871 - 882
  • [27] Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?
    Williams, David M.
    Atkinson, Michael
    Evans, Marc
    STROKE, 2023, 54 (05) : 1441 - 1451
  • [28] Glucagon-like peptide 1 (GLP-1)
    Mueller, T. D.
    Finan, B.
    Bloom, S. R.
    D'Alessio, D.
    Drucker, D. J.
    Flatt, P. R.
    Fritsche, A.
    Gribble, F.
    Grill, H. J.
    Habener, J. F.
    Holst, J. J.
    Langhans, W.
    Meier, J. J.
    Nauck, M. A.
    Perez-Tilve, D.
    Pocai, A.
    Reimann, F.
    Sandoval, D. A.
    Schwartz, T. W.
    Seeley, R. J.
    Stemmer, K.
    Tang-Christensen, M.
    Woods, S. C.
    DiMarchi, R. D.
    Tschoep, M. H.
    MOLECULAR METABOLISM, 2019, 30 : 72 - 130
  • [29] Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?
    Juris J Meier
    Michael A Nauck
    Nature Clinical Practice Endocrinology & Metabolism, 2008, 4 : 606 - 607
  • [30] Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?
    Meier, Juris J.
    Nauck, Michael A.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (11): : 606 - 607
12345